

## FOR IMMEDIATE RELEASE

Strainsforpains, Inc. Positioned at the Intersection of Federal Cannabis Reform, Medical Innovation, and AI-Driven Infrastructure Growth

NEW YORK, December 17, 2025 — Strainsforpains, Inc., f/k/a E-Buy Home, Inc. (OTC: EBYH), today highlighted the transformational impact that anticipated federal cannabis reclassification could have on medical research, healthcare innovation, and the company's long-term strategic vision.

Cannabis remains classified alongside heroin as a Schedule I substance under the Controlled Substances Act of 1970—a designation that has severely limited medical research in the United States. A proposed move to Schedule III would represent a historic policy shift, dramatically reducing regulatory barriers and enabling the Food and Drug Administration (FDA) to expand clinical research into cannabis-based treatments. This reclassification could accelerate broader medical adoption and place the U.S. on par with global leaders in cannabis research.

Y. Simon Shainberg, President of Strainsforpains and a member of the prestigious International Cannabis Research Society, has spent nearly two decades at the forefront of cannabis science and pain management research. Mr. Shainberg has consulted with hundreds of hospitals, physicians, and healthcare organizations worldwide on the therapeutic potential of medical cannabis.

“Unlocking the medical benefits of cannabis through federal reclassification is one of the most important healthcare policy shifts of our time,” said Mr. Shainberg. “It finally allows America to fully participate in the global acceptance and advancement of medical cannabis research.”

Strainsforpains collaborates with leading global institutions, including Hebrew University of Jerusalem, Harvard University, Mount Sinai, and Johns Hopkins University, integrating extensive clinical and research data into its proprietary mega-data system. These collaborations enhance the company's credibility while positioning it as a data-driven innovator in next-generation healthcare solutions.

In parallel with its healthcare initiatives, the company is strategically aligned with the explosive growth of cloud computing and artificial intelligence infrastructure. Amazon recently announced plans to invest at least \$10 billion in cloud computing and AI facilities in Salem Township, Pennsylvania, underscoring the accelerating demand for large-scale data centers nationwide.

Strainsforpains' Pennsylvania property is strategically located within the industrial grid of this multi-billion-dollar AI data center corridor expected to be developed over the next two years. Modern data centers—massive facilities housing critical IT infrastructure—require reliable access to water for evaporative cooling systems that prevent overheating. The company's facility is uniquely equipped with substantial on-site water storage capabilities, including tanks capable of sustaining millions of gallons of water, making it well-positioned to support the evolving needs of data-intensive infrastructure development.

### Management and Advisory

Mr. Shainberg brings over 17 years of cannabis research and wellness experience, including work with Dr. Raphael Mechoulam of Tel Aviv, the internationally renowned scientist who pioneered the discovery of the endocannabinoid system. His background also includes deep expertise in algorithmic methodology, reinforcing Strainsforpains' data-centric approach to healthcare and infrastructure innovation.

Dr. Michael Stern is a board-certified urologist and urological surgeon. He served on the faculty at Bastyr University School of Naturopathic Medicine for 11 years (1995–2006). Dr. Stern operated the Northwest Healthy Options Clinic in Seattle, Washington, and continues to advise patients on lifestyle issues and alternative health treatments for a wide variety of diseases, including the use of medical cannabis. He is also known for his diet book, *The Rotation Diet*.

Mr. Epstein is based in New York City and is the President and Founder of Geoval Consulting LLC, a firm that applies geological expertise and experience to evaluate prime target investment opportunities. Geoval utilizes geochemical analytical data and modeling for risk profiling to certify geological assets and property selection for private and public entities. He has over 50 publications and has served on the Board of Governors for Touro College and University for the past 20 years, acting as an Executive Director of the Touro College Center for Environmental and Geological Research.

About Strainsforpains, Inc. (OTC: EBYH), f/k/a E-Buy Home, Inc.

Strainsforpains, Inc. is an innovative healthcare data technology company located in New York, N.Y. The company's objective is to provide doctors, nurses, dispensaries, and patients access to an app that allows advanced comparison and determination of cannabis strains or brands for major illnesses in a user-friendly manner.

The proprietary app incorporates advanced artificial intelligence and collaborates with pain management departments at hospitals and healthcare professionals. The company integrates AI to expand the selection of cannabis varieties, positioning itself as a leading educational tool for pain management operations at hospitals and for physicians specializing in pain relief. The company owns a seven-acre facility in Pennsylvania.

Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society (<https://icrs.com>).

### Safe Harbor Statement

Statements in this press release that are not historical facts may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it cannot give assurance that such expectations will be attained. Investors are cautioned that forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's control. Actual results may differ materially from those projected. Additional risk factors are included in Strainsforpains, Inc.'s filings with the Securities and Exchange Commission and OTC Markets.

For Further Information and Media Contact:

Y.Simon Shainberg, CEO 1-347-218-0844 [simon@strainsforpains.com](mailto:simon@strainsforpains.com)

<https://www.strainsforpains.com/>

<https://www.facebook.com/profile.php?id=100071016855607>

<https://twitter.com/strainsforpains> [https://www.instagram.com/strains\\_for\\_pains/](https://www.instagram.com/strains_for_pains/)

[https://www.instagram.com/strains\\_for\\_pains/](https://www.instagram.com/strains_for_pains/)

<https://www.linkedin.com/company/strainsforpains/?viewAsMember=true>

<https://www.youtube.com/watch?v=E-lftNrcFLk>